Poor outcome after liver transplantation for transthyretin amyloid neuropathy in a family with an Ala36Pro transthyretin mutation: Case report
✍ Scribed by Kate R. Muller; Robert Padbury; Gary P. Jeffrey; Nicola K. Poplawski; Philip Thompson; Anne Tonkin; Hugh A. J. Harley
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 75 KB
- Volume
- 16
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.22019
No coin nor oath required. For personal study only.
✦ Synopsis
Transthyretin amyloid polyneuropathy, caused by mutations in the transthyretin gene, is a progressive condition for which liver transplantation is an established treatment. Favorable outcomes have been described in patients with the most common transthyretin mutation, Val30Met, but outcomes have been variable in patients with other mutations. We describe the cases of 2 siblings with transthyretin amyloid polyneuropathy secondary to an infrequently reported transthyretin mutation (Ala36Pro) who underwent liver transplantation with poor outcomes.